tiprankstipranks
RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)
Blurbs

RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)

In a report released on April 7, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECHResearch Report), with a price target of $79.00. The company’s shares closed yesterday at $68.22.

McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Bio-Rad Laboratories, and Maravai Lifesciences Holdings. According to TipRanks, McNamara has an average return of -8.5% and a 40.70% success rate on recommended stocks.

Currently, the analyst consensus on Bio-Techne is a Strong Buy with an average price target of $80.00.

The company has a one-year high of $89.59 and a one-year low of $51.66. Currently, Bio-Techne has an average volume of 1.07M.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TECH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bio-Techne (TECH) Company Description:

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles